Cargando…

The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis

INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted d...

Descripción completa

Detalles Bibliográficos
Autores principales: Buja, Alessandra, Miatton, Andrea, Cozzolino, Claudia, Brazzale, Alessandra Rosalba, Lo Bue, Roberta, Mercuri, Santo Raffaele, Proft, Fabian Nikolai, Kridin, Khalaf, Cohen, Arnon Dov, Damiani, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442308/
https://www.ncbi.nlm.nih.gov/pubmed/37542678
http://dx.doi.org/10.1007/s13555-023-00986-0
_version_ 1785093564667002880
author Buja, Alessandra
Miatton, Andrea
Cozzolino, Claudia
Brazzale, Alessandra Rosalba
Lo Bue, Roberta
Mercuri, Santo Raffaele
Proft, Fabian Nikolai
Kridin, Khalaf
Cohen, Arnon Dov
Damiani, Giovanni
author_facet Buja, Alessandra
Miatton, Andrea
Cozzolino, Claudia
Brazzale, Alessandra Rosalba
Lo Bue, Roberta
Mercuri, Santo Raffaele
Proft, Fabian Nikolai
Kridin, Khalaf
Cohen, Arnon Dov
Damiani, Giovanni
author_sort Buja, Alessandra
collection PubMed
description INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. RESULTS: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. CONCLUSION: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey.
format Online
Article
Text
id pubmed-10442308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-104423082023-08-23 The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis Buja, Alessandra Miatton, Andrea Cozzolino, Claudia Brazzale, Alessandra Rosalba Lo Bue, Roberta Mercuri, Santo Raffaele Proft, Fabian Nikolai Kridin, Khalaf Cohen, Arnon Dov Damiani, Giovanni Dermatol Ther (Heidelb) Original Research INTRODUCTION: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset. METHODS: In a matched case–control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented. RESULTS: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2–4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients’ specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88–7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96–4.77)], inflammatory bowel diseases [i.e., Crohn’s disease (OR 2.99 95% CI 2.20–4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61–2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36–3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30–2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57–1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41–1.53)]. CONCLUSION: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey. Springer Healthcare 2023-08-05 /pmc/articles/PMC10442308/ /pubmed/37542678 http://dx.doi.org/10.1007/s13555-023-00986-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Buja, Alessandra
Miatton, Andrea
Cozzolino, Claudia
Brazzale, Alessandra Rosalba
Lo Bue, Roberta
Mercuri, Santo Raffaele
Proft, Fabian Nikolai
Kridin, Khalaf
Cohen, Arnon Dov
Damiani, Giovanni
The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title_full The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title_fullStr The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title_full_unstemmed The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title_short The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis
title_sort prevalent comorbidome at the onset of psoriasis diagnosis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10442308/
https://www.ncbi.nlm.nih.gov/pubmed/37542678
http://dx.doi.org/10.1007/s13555-023-00986-0
work_keys_str_mv AT bujaalessandra theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT miattonandrea theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT cozzolinoclaudia theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT brazzalealessandrarosalba theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT lobueroberta theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT mercurisantoraffaele theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT proftfabiannikolai theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT kridinkhalaf theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT cohenarnondov theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT damianigiovanni theprevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT bujaalessandra prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT miattonandrea prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT cozzolinoclaudia prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT brazzalealessandrarosalba prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT lobueroberta prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT mercurisantoraffaele prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT proftfabiannikolai prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT kridinkhalaf prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT cohenarnondov prevalentcomorbidomeattheonsetofpsoriasisdiagnosis
AT damianigiovanni prevalentcomorbidomeattheonsetofpsoriasisdiagnosis